Format

Send to

Choose Destination
Water Res. 2015 Jun 1;76:187-200. doi: 10.1016/j.watres.2015.02.059. Epub 2015 Mar 12.

Occurrence of selected pharmaceuticals at drinking water purification plants in Japan and implications for human health.

Author information

1
Water Management Section, Department of Environmental Health, National Institute of Public Health, 2-3-6 Wako, Saitama, 351-0197, Japan. Electronic address: simazaki@niph.go.jp.
2
Division of Environmental Chemistry, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo, 158-8501, Japan.
3
Division of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
4
Water Management Section, Department of Environmental Health, National Institute of Public Health, 2-3-6 Wako, Saitama, 351-0197, Japan.
5
Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano, Tokyo, 164-8530, Japan.

Abstract

The present study was performed to determine the occurrence of 64 pharmaceuticals and metabolites in source water and finished water at 6 drinking water purification plants and 2 industrial water purification plants across Japan. The analytical methods employed were sample concentration using solid-phase extraction cartridges and instrumental analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS), liquid chromatography with mass spectrometry (LC/MS), or trimethylsilyl derivatization followed by gas chromatography with mass spectrometry (GC/MS). Thirty-seven of the 64 target substances were detected in the source water samples. The maximum concentrations in the source water were mostly below 50 ng/L except for 13 substances. In particular, residual concentrations of iopamidol (contrast agent) exceeded 1000 ng/L at most facilities. Most of the residual pharmaceuticals and metabolites in the source water samples were removed in the course of conventional and/or advanced drinking water treatments, except for 7 pharmaceuticals and 1 metabolite, i.e., amantadine, carbamazepine, diclofenac, epinastine, fenofibrate, ibuprofen, iopamidol, and oseltamivir acid. The removal ratios of the advanced water treatment processes including ozonation and granular activated carbon filtration were typically much higher than those of the conventional treatment processes. The margins of exposure estimated by the ratio of daily minimum therapeutic dose to daily intake via drinking water were substantial, and therefore the pharmacological and physiological impacts of ingesting those residual substances via drinking water would be negligible.

KEYWORDS:

Drinking water; Pharmaceutical; Source water; Therapeutic dose; Water treatment

PMID:
25835589
DOI:
10.1016/j.watres.2015.02.059
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center